Phase 3 Clinical Trials With Primary Completion Dates in July 2018
This is a list of Phase 3 trials with primary completion dates in July 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|AMRN||Amarin Corporation plc||2018-07-01||Phase 3||NCT01492361||A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.|
|ANIK||Anika Therapeutics Inc.||2018-07-01||Phase 3||NCT03390036||Study of Cingalâ¢ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up|
|EDGE||Edge Therapeutics, Inc.||2018-07-01||Phase 3||NCT02790632||Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage|
|GRFS||Grifols, S.A.||2018-07-01||Phase 3||NCT02796937||Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency|
|MESO||Mesoblast Limited||2018-07-01||Phase 3||NCT00482092||Evaluation of PROCHYMALÂ® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease|
|RDHL||Redhill Biopharma Ltd.||2018-07-01||Phase 3||NCT03198507||ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator|
|REPH||Recro Pharma, Inc.||2018-07-01||Phase 3||NCT03323385||Evaluation of Preoperative N1539 in Colorectal Surgery|
|UTHR||United Therapeutics Corporation||2018-07-01||Phase 3||NCT01560624||Trial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial Hypertension|